719
Participants
Start Date
September 30, 2000
Primary Completion Date
March 31, 2004
Study Completion Date
March 31, 2004
Pioglitazone
Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
Rosiglitazone
Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
New York
Staten Island
East Setauket
Endwell
Rochester
Philadelphia
Pottstown
Baltimore
Frederick
Mechanicsville
Virginia Beach
Newport News
Durham
Greenville
Charlotte
Wilmington
Morehead City
Mt. Pleasant
Fayetteville
Atlanta
Longwood
Miami
Miami
Birmingham
Anniston
Knoxville
Memphis
Columbus
Franklin
Indianapolis
South Bend
Milwaukee
Minneapolis
Chicago
Chesterfield
New Orleans
Tulsa
Dallas
Houston
Conroe
Lake Jackson
Beaumont
San Antonio
Aurora
Englewood
Idaho Falls
Ogden
Tucson
Los Angeles
Palos Verdes Estates
San Diego
Santa Barbara
Concord
Fremont
Santa Rosa
Honolulu
Portland
Salem
Federal Way
Wenatchee
Avon
Hamden
Salisbury
South Yarmouth
Waltham
Omaha
Providence
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Takeda
INDUSTRY